Transfusion Therapy for Patients Critically Ill With Cancer
- 1 February 1996
- journal article
- review article
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 7 (1) , 37-45
- https://doi.org/10.1097/00044067-199602000-00004
Abstract
Patients with cancer receive antineoplastic therapy that affect their ability to produce and maintain circulating levels of blood cells at any given time. Frequent and varied transfusion requirements necessitate a highly developed and specialized practice of blood component therapy in cancer care. In this article, the author discusses factors affecting the selection of blood components and the influence that expert critical care nurses can contribute to safe and effective transfusion therapy. Administration of leukocyte-poor or cytomegalovirus-negative erythrocytes, pheresed platelets, and granulocyte transfusions are described.Keywords
This publication has 19 references indexed in Scilit:
- Transfusion requirements, risks, and costs for patients with malignancyTransfusion, 1995
- Blood Component Replacement TherapyCritical Care Nursing Clinics of North America, 1993
- Transfusion therapy in critical care nursingCritical Care Nursing Quarterly, 1990
- Massive TransfusionSouthern Medical Journal, 1990
- Platelet transfusion therapy for thrombocytopeniaSeminars in Oncology Nursing, 1990
- Nursing considerations in the administration of blood component therapySeminars in Oncology Nursing, 1990
- Blood support for the myelosuppressed patientSeminars in Oncology Nursing, 1990
- The value of 10‐minute posttransfusion platelet countsTransfusion, 1988
- Platelet PreservationNew England Journal of Medicine, 1969
- Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia.Journal of Clinical Investigation, 1966